| Project/Area Number |
13307057
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Meikai University |
|---|
Principal Investigator |
SAKASHITA Hideaki Meikai University, Dentistry, Professor, 歯学部, 教授 (10178551)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
FUKUDA Masakatsu Meikai University, Dentistry, Assistant Professor, 歯学部, 講師 (10311614)
SAKAGAMI Hiroshi Meikai University, Dentistry, Professor, 歯学部, 教授 (50138484)
KUSAMA Kaoru Meikai University, Dentistry, Professor, 歯学部, 教授 (20130479)
山本 美朗 明海大学, 歯学部, 教授 (40049383)
|
|---|
| Project Period (FY) |
2001 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥43,160,000 (Direct Cost: ¥33,200,000、Indirect Cost: ¥9,960,000)
Fiscal Year 2003: ¥14,040,000 (Direct Cost: ¥10,800,000、Indirect Cost: ¥3,240,000)
Fiscal Year 2002: ¥13,650,000 (Direct Cost: ¥10,500,000、Indirect Cost: ¥3,150,000)
Fiscal Year 2001: ¥15,470,000 (Direct Cost: ¥11,900,000、Indirect Cost: ¥3,570,000)
|
|---|
| Keywords | oral cancer / squamous cell carcinoma / gene alteration / p53 / apoptosis / anticancer drug / dendritic cell / VEGF |
|---|
| Research Abstract |
1. The analysis of cytotoxic effect and its mechanism of apoptosis-induced drug for oral cancer cell lines. : The apoptosis-induced drug does not always reveal high tumor selectivity. Low-molecular-weight polyphenol inhibited NO production from LPS-stimulated macrophage.
2. Analysis of p53 gene alterations in primary oral cancer. : At first, immunohistochemistry using MAb p53 antibody was performed, 18 of 33 cases (54.5%) were positive. Then p53 gene alteration was analyzed by PCR-SSCP and direct sequencing. As the results, p53 point mutations were detected in 14 of 33 cases (42.4%). In addition to last year, p53 gene alterations were totally detected in 19 of 54 cases (35.2%).
3. Anticancer drug sensitivity test for individual patient. : Case1 : 5-FU : 78.2%, CDDP : 69.2 %, PEP : 0 %, TXL : 60 %, 254-S : 83.5% ; Case 2 : 5-FU : 53.2%, CDDP : 46.3%, PEP : 41.1%, TXL : 73.3%, 254-S : 68.8 % ; Case 3 : CDDP : 48.8%, PEP : 33.2%, TXL : 90.3%, 254-S : 67.9% ; Case 4 : We could not get informed concent ; Case 5 : Assay was failed. ; Case 6 : 5-FU : 37.8, CDDP : 27.1, 254-S : 52.9, TXL : 62, PEP : 3.9(%) ; Case 7 : CDDP : 27.1, PEP : 83(%)
4. The basic study on lymphocyte activating therapy. : Immortalization of cancer cells was not succeed yet. VEGF was detected from various oral cancer cell lines. The culture of Dendritic cells (DC) in the medium included VEGF inhibited the maturation of it. To inhibit the action of VEGF is a key way for the success of lymphocyte activating therapy.
|
